Newsletter | February 2, 2026

02.02.26 -- BoB@JPM: Ron Cooper, enGene

FEATURED ARTICLE

BoB@JPM: Ron Cooper, enGene

 On this week's episode of the Business of Biotech -- on location at the J.P. Morgan Healthcare Conference -- we're speaking with Ron Cooper, CEO and Board Member at enGene, to unpack how he scaled Albireo from a small research shop to a global commercial company, and why he’s now betting on nonviral gene therapy at enGene to help patients with non-muscle invasive bladder cancer keep their bladders.

INDUSTRY INSIGHTS

T3P – A Green Solution For Peptide Coupling, Water Removal Reactions

The session focuses on the use of T3P (propanephosphonic acid anhydride) in amidation and peptide coupling reactions, including both liquid-phase and solid-phase peptide synthesis.

Recruitment To Screening: Bridging The Gap

Explore how providing tracked transportation for patients can streamline recruitment, improve site conversion rates, and deliver measurable ROI for clinical trials.

How Direct‑To‑Patient Rescue Studies Speed Clinical Trial Enrollment

When enrollment stalls, shifting from site‑centric models to a tech‑enabled rescue approach can speed timelines and broaden diversity by delivering high‑quality, pre‑qualified patient referrals.

AI Implementation To Enhance Quality

Discover how solutions driven by artificial intelligence can enhance compliance, optimize workflows, and drive efficiency in biopharma operations.

Why You Should Include SDOH In Clinical Trial Recruitment

Embrace a broader approach to diversity in clinical trials by addressing social determinants of health and designing inclusive studies that ensure equitable representation and access to all patients.